Scientific Publications by FDA Staff
PLoS One 2013 Nov 14;8(11):e79304
The Development of an Experimental Multiple Serogroups Vaccine for Neisseria meningitidis.
Pinto VB, Burden R, Wagner A, Moran EE, Lee CH
A native outer membrane vesicles (NOMV) vaccine was developed from three antigenically diverse strains of Neisseria meningitidis that express the L1,8, L2, and L3,7 lipooligosaccharide (LOS) immunotypes, and whose synX, and lpxL1 genes were deleted.. Immunogenicity studies in mice showed that the vaccine induced bactericidal antibody against serogroups B, C, W, Y and X N. meningitidis strains. However, this experimental NOMV vaccine was not effective against serogroup A N. meningitidis strains. N. meningitidis capsular polysaccharide (PS) from serogroups A, C, W and Y were effective at inducing bactericidal antibody when conjugated to either tetanus toxoid or the fHbp1-fHbp2 fusion protein fHbp(1+2). The combination of the NOMV vaccine and the N. meningitidis serogroup A capsular polysaccharide (MAPS) protein conjugate was capable of inducing bactericidal antibodies against a limited number of N. meningitidis strains from serogroups A, B, C, W, Y and X tested in this study.
|Category: Journal Article|
|PubMed ID: #24244473||DOI: 10.1371/journal.pone.0079304|
|PubMed Central ID: #PMC3828347|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2013-12-20|